Pharmaceutical compositions comprising L-leucovorin
Compositions comprising a calcium salt of L-leucovorin may be prepared that have a higher concentration of L-leucovorin than may be prepared using racemic leucovorin under similar conditions. Thus, some pharmaceutical compositions described herein may comprise a calcium salt of L-leucovorin at a relatively high concentration, such as at least about 15 mg/mL. Such a composition may be a stable aqueous solution, and may have near physiological pH, such as about 6 to about 8. Some pharmaceutical compositions may be substantially free of D-leucovorin, and may contain either: a) no EDTA, or b) less than about 1 mg/ml of EDTA. These compositions may be prepared, for example, by sonicating a mixture comprising the solid calcium salt of L-leucovorin and water. In some compositions, a calcium salt of L-leucovorin may be sufficiently soluble that it does not precipitate when it is injected.
1. A pharmaceutical composition comprising a calcium salt of L-leucovorin at a concentration greater than about 20 mg/mL, wherein the composition is a stable aqueous solution having a pH of about 6 to about 8, is substantially free of D-leucovorin, and contains either: a) no EDTA, or b) less than about 1 mg/mL of EDTA; and wherein the aqueous solution remains free of precipitates for at least about 20 hours.
2. The pharmaceutical composition of claim 1 , having a pH of about 7.2 to about 7.8.
3. The pharmaceutical composition of claim 1 , which is substantially free of calcium complexing agents.
4. The pharmaceutical composition of claim 1 , wherein the concentration of the calcium salt of L-leucovorin is about 25 mg/mL to about 50 mg/mL.
5. The pharmaceutical composition of claim 1 , further comprising sodium chloride.
6. The pharmaceutical composition of claim 1 , consisting essentially of a calcium salt of L-leucovorin, and water or aqueous sodium chloride.
7. The pharmaceutical composition of claim 1 , consisting essentially of a calcium salt of L-leucovorin; sodium chloride; hydrochloric acid, sodium hydroxide, or a combination thereof; and water.
8. The pharmaceutical composition of claim 1 , wherein the calcium salt of L-leucovorin is sufficiently soluble that it does not precipitate on storage.
9. The pharmaceutical composition of claim 1 , wherein the calcium salt of L-leucovorin has been dissolved in the composition for at least 2 hours.
10. The pharmaceutical composition of claim 1 , wherein the calcium salt of L-leucovorin has been dissolved in the composition for at least 20 hours.
11. A method of dissolving a calcium salt of L-leucovorin in water to obtain the pharmaceutical composition of claim 1 , the method comprising sonicating a mixture of a solid form of the calcium salt of L-leucovorin in saline until the calcium salt of L-leucovorin is completely dissolved in the saline.
12. The method of claim 11 , wherein the mixture is sonicated for at least about 30 minutes.
13. The method of claim 11 , wherein the mixture is sonicated at a temperature of at least about 40° C.